MeSH term
Frequency | Condition_Probility | Adult | 25 | 0.0 |
Humans | 117 | 0.0 |
Male | 53 | 0.0 |
Middle Aged | 17 | 0.0 |
Risk Factors | 4 | 0.0 |
Animals | 70 | 0.0 |
Base Sequence | 18 | 0.0 |
Cell Line | 9 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Genomic Imprinting | 2 | 1.0 |
Mice | 25 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 100 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Potassium Channels/*metabolism | 4 | 10.0 |
Research Support, U.S. Gov't, P.H.S. | 30 | 0.0 |
CHO Cells | 11 | 0.0 |
*Cation Transport Proteins | 18 | 8.0 |
*DNA-Binding Proteins | 17 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Electrophysiology | 16 | 3.0 |
Female | 56 | 0.0 |
Hamsters | 14 | 0.0 |
Immunoblotting | 2 | 0.0 |
In Vitro | 6 | 0.0 |
Membrane Potentials/physiology | 5 | 5.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Oocytes/metabolism | 10 | 5.0 |
Patch-Clamp Techniques | 23 | 5.0 |
*Potassium Channels, Voltage-Gated | 93 | 35.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Tissue Distribution | 4 | 0.0 |
*Trans-Activators | 17 | 2.0 |
Xenopus | 12 | 2.0 |
Amino Acid Sequence | 24 | 0.0 |
Child, Preschool | 13 | 0.0 |
Electrocardiography | 21 | 6.0 |
English Abstract | 8 | 0.0 |
Long QT Syndrome/*genetics/therapy | 2 | 66.0 |
Molecular Sequence Data | 31 | 0.0 |
Pedigree | 27 | 0.0 |
Phenotype | 21 | 0.0 |
*Point Mutation | 3 | 0.0 |
Prognosis | 6 | 0.0 |
Sodium Channels/*genetics | 5 | 5.0 |
Mutation | 22 | 0.0 |
Potassium Channels/genetics | 7 | 14.0 |
*Mutation | 20 | 0.0 |
Polymorphism, Single-Stranded Conformational | 16 | 0.0 |
Potassium Channels/*genetics | 32 | 24.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Anti-Arrhythmia Agents/pharmacology | 2 | 11.0 |
Immunohistochemistry | 3 | 0.0 |
Potassium/metabolism | 6 | 5.0 |
Potassium Channel Blockers | 4 | 15.0 |
Protein Binding/physiology | 2 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Blotting, Northern | 3 | 0.0 |
Cloning, Molecular | 9 | 0.0 |
Gene Expression | 8 | 0.0 |
Microinjections | 4 | 1.0 |
Myocardium/*metabolism | 2 | 0.0 |
Rats | 9 | 0.0 |
Sequence Alignment | 8 | 0.0 |
Sequence Homology, Amino Acid | 10 | 0.0 |
Rats, Wistar | 3 | 0.0 |
Gene Therapy | 2 | 0.0 |
Potassium Channels/*genetics/*physiology | 2 | 50.0 |
Transfection | 14 | 0.0 |
Electric Conductivity | 13 | 7.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Ion Channel Gating/*drug effects | 2 | 20.0 |
Oocytes | 7 | 6.0 |
Potassium Channels/genetics/*physiology | 3 | 27.0 |
Xenopus laevis | 17 | 3.0 |
Atrial Fibrillation/*genetics | 2 | 66.0 |
COS Cells | 10 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
China | 5 | 1.0 |
Ion Transport | 2 | 2.0 |
Potassium Channels, Voltage-Gated/*genetics | 4 | 50.0 |
Arrhythmia/genetics | 3 | 60.0 |
Cells, Cultured | 6 | 0.0 |
Protein Subunits | 2 | 0.0 |
Ammonium Compounds/pharmacology | 2 | 8.0 |
Barium/pharmacology | 2 | 25.0 |
Clotrimazole/pharmacology | 2 | 15.0 |
Ions | 3 | 3.0 |
Potassium Channel Blockers/pharmacology | 2 | 6.0 |
Long QT Syndrome/*genetics | 17 | 43.0 |
Mutation, Missense | 8 | 1.0 |
Aged | 7 | 0.0 |
Arrhythmia/*genetics | 3 | 37.0 |
Comparative Study | 12 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Family Health | 10 | 0.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Japan/epidemiology | 2 | 0.0 |
Binding Sites | 5 | 0.0 |
Ion Channel Gating | 3 | 4.0 |
Kinetics | 8 | 0.0 |
Membrane Potentials/drug effects/physiology | 3 | 3.0 |
Potassium Channels/metabolism | 2 | 5.0 |
Adolescent | 18 | 0.0 |
DNA Primers | 4 | 0.0 |
Genes, Dominant | 2 | 0.0 |
Potassium Channels/genetics/*metabolism | 7 | 26.0 |
Colon/chemistry | 2 | 10.0 |
Rabbits | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Introns/genetics | 2 | 0.0 |
Long QT Syndrome/genetics | 8 | 57.0 |
Mutation/*genetics | 6 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Temperature | 2 | 0.0 |
DNA/chemistry/genetics | 4 | 0.0 |
*Gene Silencing | 2 | 1.0 |
*Genomic Imprinting | 3 | 1.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Action Potentials/physiology | 2 | 4.0 |
Gene Expression/physiology | 2 | 0.0 |
Potassium Channels/*genetics/metabolism | 3 | 10.0 |
Adrenergic beta-Antagonists/*therapeutic use | 3 | 8.0 |
Child | 12 | 0.0 |
Genotype | 10 | 0.0 |
Infant | 5 | 0.0 |
Infant, Newborn | 4 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Treatment Outcome | 3 | 0.0 |
Action Potentials/drug effects | 3 | 8.0 |
Indoles/pharmacology | 3 | 1.0 |
Pyridines/pharmacology | 3 | 1.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
DNA Mutational Analysis | 16 | 0.0 |
Haplotypes | 2 | 0.0 |
Electrochemistry | 2 | 2.0 |
Models, Molecular | 5 | 0.0 |
Colon/metabolism | 2 | 1.0 |
Disease Models, Animal | 2 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Alleles | 3 | 0.0 |
Beckwith-Wiedemann Syndrome/*genetics | 2 | 4.0 |
Chromosomes, Human, Pair 11 | 2 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Time Factors | 5 | 0.0 |
Point Mutation | 4 | 0.0 |
Potassium Channels/*genetics/*metabolism | 2 | 18.0 |
Ion Channel Gating/drug effects/*physiology | 4 | 30.0 |
Potassium/pharmacokinetics | 2 | 50.0 |
Potassium Channels/*physiology | 2 | 6.0 |
Gastric Acid/*secretion | 2 | 3.0 |
Gastric Acidity Determination | 2 | 9.0 |
Species Specificity | 2 | 0.0 |
Long QT Syndrome/*drug therapy/*genetics | 2 | 100.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Mammals | 2 | 0.0 |
Oocytes/physiology | 6 | 5.0 |
Action Potentials | 4 | 6.0 |
Long QT Syndrome/*genetics/physiopathology | 5 | 62.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 2 | 2.0 |
Dinoprostone/pharmacology | 2 | 2.0 |
Phosphodiesterase Inhibitors/pharmacology | 2 | 1.0 |
Tetraethylammonium/pharmacology | 2 | 9.0 |
In Situ Hybridization | 3 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
*Exercise Test | 2 | 5.0 |
Embryo | 2 | 0.0 |
Heterozygote | 2 | 0.0 |
Protein Binding | 4 | 0.0 |
Chromans/pharmacology | 2 | 8.0 |
Sulfonamides/pharmacology | 2 | 1.0 |
*Mutation, Missense | 2 | 0.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
*Genetic Screening | 3 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Genes, Dominant/*genetics | 2 | 2.0 |
Genes, Recessive/*genetics | 3 | 5.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Aged, 80 and over | 4 | 0.0 |
Point Mutation/*genetics | 2 | 0.0 |
Potassium Channels/chemistry/*genetics | 2 | 20.0 |
Heart/physiology | 2 | 5.0 |
Potassium/pharmacology | 2 | 3.0 |
Potassium Channels/*chemistry/drug effects/*physiology | 2 | 100.0 |
Recombinant Proteins/chemistry/drug effects/metabolism | 2 | 20.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Structure-Activity Relationship | 3 | 0.0 |
Syndrome | 2 | 0.0 |
*Heterozygote | 3 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Sodium Channels/genetics | 3 | 12.0 |
Polymorphism, Genetic | 3 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Myocardium/metabolism | 2 | 0.0 |
Cation Transport Proteins/genetics | 2 | 12.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Genetic Screening | 2 | 0.0 |
Long QT Syndrome/diagnosis/*genetics | 2 | 50.0 |
Long QT Syndrome/genetics/*physiopathology | 2 | 100.0 |
Models, Genetic | 2 | 0.0 |
Electric Stimulation | 3 | 1.0 |
Genetic Screening/methods | 2 | 1.0 |
Benzodiazepines/pharmacology | 2 | 20.0 |
Potassium Channels, Voltage-Gated | 2 | 3.0 |
*Variation (Genetics) | 2 | 0.0 |
Epilepsy, Generalized/*genetics | 2 | 7.0 |
Ion Channel Gating/physiology | 2 | 8.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
Algorithms | 4 | 1.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Anti-Arrhythmia Agents/*pharmacology | 2 | 10.0 |
Potassium Channels/genetics/metabolism/*physiology | 2 | 66.0 |
*Potassium Channels, Calcium-Activated | 2 | 5.0 |
*Electrocardiography | 2 | 3.0 |
United States | 2 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
Nucleic Acid Denaturation | 2 | 2.0 |
Ion Channel Gating/drug effects | 3 | 15.0 |
Potassium Channel Blockers/*pharmacology | 2 | 33.0 |
Cause of Death | 2 | 1.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Potassium Channels/*chemistry/metabolism | 2 | 66.0 |
